Loading organizations...
§ Government Office · C/Cid, 4, 28001 Madrid, Spain
Venture capital investment initiative channeling risk capital for technology-based companies and SMEs in Spain.
CDTI Innovación's INNVIERTE program is a venture capital investment initiative based in Spain that channels risk capital into technology-based startups and innovative small and medium-sized enterprises. Operating as a public-private collaboration model supervised by Spain's National Securities Market Commission (CNMV), the entity functions through a closed collective investment vehicle structure. The program has committed over 384 million euros across 20 investment vehicles to back more than 250 companies, alongside an additional 431 million euros deployed through co-investment lines in at least 144 enterprises. INNVIERTE manages capital allocations through notable investment vehicles such as 4Founders Capital Fund III and Next Technology Ventures to support companies operating in sectors like artificial intelligence and energy transition. The initiative was originally launched in 2012 by founder CDTI Innovation as part of the broader national science, technology, and innovation strategy.
The program's primary objective is to support innovative companies as an investment firm, operating within the framework of the Spanish Science, Technology, and Innovation Strategy.
The INNVIERTE program invests in a range of innovative companies, including biotechnology startups and other ventures such as HONEXT, Nuubo, Next-Gen Leather, ONA Therapeutics, Ingelia, and Gyala Therapeutics.
The INNVIERTE program is part of CDTI Innovación, which is a public organization under the Spanish Ministry of Science and Innovation, indicating its operation within a governmental framework.
The program's primary objective is to support innovative companies as an investment firm, operating within the framework of the Spanish Science, Technology, and Innovation Strategy.
The INNVIERTE program invests in a range of innovative companies, including biotechnology startups and other ventures such as HONEXT, Nuubo, Next-Gen Leather, ONA Therapeutics, Ingelia, and Gyala Therapeutics.
The INNVIERTE program is part of CDTI Innovación, which is a public organization under the Spanish Ministry of Science and Innovation, indicating its operation within a governmental framework.
CDTI Innovación's INNVIERTE program has 2 tracked investments across 2 companies. The latest tracked deal is $3.2M Seed in Orikine Bio in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 2, 2026 | Orikine Bio | $3.2M Seed | — | AdBio Partners, Asabys Partners |
| Jan 30, 2026 | Padmi | $962K Venture Round | — | Swanlaab Venture Factory |
As an investor, the program has been noted for its participation in funding rounds for a range of enterprises. These include biotechnology startups, as well as companies such as HONEXT, Nuubo, Next-Gen Leather, ONA Therapeutics, Ingelia, and Gyala Therapeutics. Its involvement typically appears alongside other investors, indicating a collaborative approach to funding innovative ventures.
CDTI Innovación, the parent entity, is a public organization under the Spanish Ministry of Science and Innovation. The INNVIERTE program's activities are therefore aligned with public policy goals to stimulate innovation and support the commercialization of new technologies. This governmental backing provides a stable foundation for its investment initiatives.
Through its investments, the INNVIERTE program contributes to the development of high-growth potential companies across various industries. Its focus on supporting the Spanish innovation ecosystem underscores its strategic importance in driving technological progress and creating economic value within the country.